Loss of Chromatin-Remodeling Proteins and/or CDKN2A Associates With Metastasis of Pancreatic Neuroendocrine Tumors and Reduced Patient Survival Times - Gastroenterology
UPMCSurgicalOncology (@UPMCSurgOnc) / Twitter
Melissa Hogg (@HoggNDMD) / Twitter
Dr. Jason Luke, MD – Pittsburgh, PA | Oncology
Melissa Hogg (@HoggNDMD) / Twitter
Dr. Dwight E. Heron, MD | Pittsburgh, PA | Radiation Oncologist | US News Doctors
Jennifer Xavier - Research Associate Professor - University of Pittsburgh | LinkedIn
Melissa Hogg (@HoggNDMD) / Twitter
UPMCSurgicalOncology (@UPMCSurgOnc) / Twitter
Jennifer Xavier - Research Associate Professor - University of Pittsburgh | LinkedIn
Melissa Hogg (@HoggNDMD) / Twitter
Melissa Hogg (@HoggNDMD) / Twitter
Melissa Hogg (@HoggNDMD) / Twitter
Dr. James P. Ohr, DO | Pittsburgh, PA | Oncologist | US News Doctors
Melissa Hogg (@HoggNDMD) / Twitter
Melissa Hogg (@HoggNDMD) / Twitter
SMAD4 loss is associated with response to neoadjuvant chemotherapy plus hydroxychloroquine in patients with pancreatic adenocarcinoma - Fei - - Clinical and Translational Science - Wiley Online Library
UPMCSurgicalOncology (@UPMCSurgOnc) / Twitter
Melissa Hogg (@HoggNDMD) / Twitter
References in A pancreatic cancer multidisciplinary clinic: insights and outcomes - Journal of Surgical Research
Melissa Hogg (@HoggNDMD) / Twitter
Melissa Hogg (@HoggNDMD) / Twitter
See Article that... - UPMC Surgical Oncology Services | Facebook
